Thursday, 20 Feb 2020

You are here

Good Pregnancy Outcomes for DMARD Exposed JIA Patients

A study of pregnancy outcomes in 98 women with juvenile idiopathic arthritis (JIA) who were exposed to DMARDs shows no increased risk of major adverse pregnancy outcomes.

A total of 152 pregnancies in 98 women with JIA and 39 pregnancies involving 21 male patients as partners were reviewed. The majority had a polyarticular JIA (61%). The average age at first pregnancy was 24.1 years, and their mean disease duration was 13.8 years.

Patients were selected because of their DMARD exposure, which averaged to 9.5 years of exposure, with 90% having received biologics before. Half of the pregnancies occurred during DMARD exposure, mostly with etanercept.

There were no significant differences in pregnancy outcomes when comparing DMARD-exposed and DMARD-unexposed pregnancies.  Adverse pregnancy outcomes (spontaneous abortion-13.1% or congenital anomaly-3.6%) occurred at rates equal to or below expected background rates.

Rates of premature birth (12.3%) and cesarean section (37.7%) were slightly above those in the German birthing population. 

Young adults with JIA, or their spouses, who are exposed to DMARD therapy do not appear to be at annincreased risk of adverse pregnancy outcomes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Seronegativity on the Rise in RA

Although the overall incidence rates of rheumatoid arthritis (RA) have remained stable over recent decades, there has been a significant increase in seronegative cases, a retrospective study showed.

Alcohols Net Zero Effect in Rheumatoid Arthritis

A report from The National Databank for Rheumatic Disease addressed the impact of alcohol on disease activity and mortality in rheumatoid arthritis (RA) and found that alcohol use was not associated with changes in disease activity or mortality, after addressing confounders. 

DMARD Inertia by Registry Rheumatologists

A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).

Bariatric Weight Loss Fails to Alter RA Risk

Obesity has been shown to be a risk factor for the onset of rheumatoid arthritis (RA) and also shown to affect outcomes by impairing responses to many DMARD therapies. A Swiss study of RA patients undergoing bariatric surgery failed to show that bariatric surgery and weight loss had any effect on the incidence of RA.

Limited Advantage to Very Early vs. Delayed Etanercept in RA

The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.